Biotech Values

[drbio45]

But the timing of Gold's sale sends a bad signal to investors. It doesn't fill me with warm, fuzzy -- or confident -- feelings. If I were in Gold's shoes (and I'm most decidedly not), I would have waited for the FDA decision before selling shares.

That's just me -- I'm not here to tell Gold that he screwed up or that he did the right thing. I still like Dendreon. I still like Provenge, and I think it gets approved on May 15.

I don't have a position in Dendreon but Fuerstein sounds very amateurish when he says the above. If Gold was selling before the meeting that would have sent a bad signal. He is selling after the meeting when the data is out in the open. Everyone is on an even playing field and Gold is taking profits. The sale should not effect his analysis of that data he sees and the sale shouldn't make him more nervous.

And unless he is in the position of selling 2 million dollars worth of stock in one day he shouldn't say that he would have held the stock, because he really doesn't know that. As a professional he should know that trading opportunities sometimes have you do things that you didn't intend to do.